Effect of the ethanolic extract of green tea and green coffee on cardiac fibrosis attenuation by suppressing activin-a and collagen-1 gene expression

Background: Progression in the severity of metabolic syndrome (MetS) contributes to the development of cardiovascular disease. It leads to changes in the histological structure of the heart, known as cardiac fibrosis. Cardiac fibrosis can be identified from the high levels of the profibrotic molecul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Chomsy, Indah Nur, Rohman, Mohammad Saifur, Khotimah, Husnul, Bramantyo, Bernadus Bernardino, Auzan, Asyrafly, Lukitasari, Mifetika, Nugroho, Dwi Adi
Format: Tagungsbericht
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Progression in the severity of metabolic syndrome (MetS) contributes to the development of cardiovascular disease. It leads to changes in the histological structure of the heart, known as cardiac fibrosis. Cardiac fibrosis can be identified from the high levels of the profibrotic molecule, such as activin-a and collagen-1. Aim: This study aims to determine the effect of therapy chlorogenic acid (CGA) from green coffee and epigallocatechin-3-gallate (EGCG) from green tea extract on activin-1 and collagen-1 gene expression the rat MetS model. Methods: Twenty-five male MetS rats (Sprague-Dawley) were divided into two control groups and three therapy groups (n=5). The administration of the CGA 200mg/kgbw and EGCG 300mg/kgbw were given orally. After eight weeks of treatment, rats were euthanized, then mRNA expression of activin-1 and collagen-1 were measured. Results: There is a significant effect of giving CGA and EGCG a therapy to suppress the activin-a (P-value= 0.001) and collagen-1 (P-value= 0.016) gene expressions in the rat MetS model. The correlation between the two genes expression shows a positive association. Conclusion: This study shows that CGA and EGCG are potential agents to prevent cardiac fibrosis as a clinical manifestation in metabolic syndrome.
ISSN:0094-243X
1551-7616
DOI:10.1063/5.0099004